OBJECTIVE: To determine whether intraocular treatment with vascular endothelial growth factor (VEGF) inhibitors change systemic endothelial function (EF) in patients with neovascular age-related macular degeneration (AMD). METHODS: In this prospective, randomized, 2-center, double-masked controlled interventional trial, patients with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry AMD served as controls. The primary endpoint was the change in EF assessed by flow-mediated dilatation (FMD) after 2 months of treatment with VEGF inhibitors in patients with AMD compared to patients with dry AMD. FMD was assessed with B-mode high-resolution ultrasonography of the left brachial artery. RESULTS:24 patients with neovascular AMD and 26 patients with dry ADM were included in the trial. Treatment with VEGF inhibitors did not significantly change FMD (from 4.7 ± 2.4 to 3.9 ± 1.9% after 8 weeks, p = 0.07, and to 5.1 ± 2.0% after 1 year; p = 0.93 vs. baseline, respectively). CONCLUSIONS:EF did not significantly differ between patients with neovascular AMD treated with intravitreal VEGF inhibition and patients with dry AMD.
RCT Entities:
OBJECTIVE: To determine whether intraocular treatment with vascular endothelial growth factor (VEGF) inhibitors change systemic endothelial function (EF) in patients with neovascular age-related macular degeneration (AMD). METHODS: In this prospective, randomized, 2-center, double-masked controlled interventional trial, patients with neovascular and dry AMD were enrolled. Eligible neovascular AMDpatients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry AMD served as controls. The primary endpoint was the change in EF assessed by flow-mediated dilatation (FMD) after 2 months of treatment with VEGF inhibitors in patients with AMD compared to patients with dry AMD. FMD was assessed with B-mode high-resolution ultrasonography of the left brachial artery. RESULTS: 24 patients with neovascular AMD and 26 patients with dry ADM were included in the trial. Treatment with VEGF inhibitors did not significantly change FMD (from 4.7 ± 2.4 to 3.9 ± 1.9% after 8 weeks, p = 0.07, and to 5.1 ± 2.0% after 1 year; p = 0.93 vs. baseline, respectively). CONCLUSIONS: EF did not significantly differ between patients with neovascular AMD treated with intravitreal VEGF inhibition and patients with dry AMD.
Authors: John Deanfield; Ann Donald; Claudio Ferri; Cristina Giannattasio; Julian Halcox; Sean Halligan; Amir Lerman; Giuseppe Mancia; James J Oliver; Achille C Pessina; Damiano Rizzoni; Gian Paolo Rossi; Antonio Salvetti; Ernesto L Schiffrin; Stefano Taddei; David J Webb Journal: J Hypertens Date: 2005-01 Impact factor: 4.844
Authors: T K Rosengart; L Y Lee; S R Patel; T A Sanborn; M Parikh; G W Bergman; R Hachamovitch; M Szulc; P D Kligfield; P M Okin; R T Hahn; R B Devereux; M R Post; N R Hackett; T Foster; T M Grasso; M L Lesser; O W Isom; R G Crystal Journal: Circulation Date: 1999-08-03 Impact factor: 29.690
Authors: Isabella Sudano; Andreas J Flammer; Daniel Périat; Frank Enseleit; Matthias Hermann; Mathias Wolfrum; Astrid Hirt; Priska Kaiser; David Hurlimann; Michel Neidhart; Steffen Gay; Johannes Holzmeister; Juerg Nussberger; Pavani Mocharla; Ulf Landmesser; Sarah R Haile; Roberto Corti; Paul M Vanhoutte; Thomas F Lüscher; Georg Noll; Frank Ruschitzka Journal: Circulation Date: 2010-10-18 Impact factor: 29.690
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258
Authors: Stephan Winnik; Christine Lohmann; Giovanni Siciliani; Tobias von Lukowicz; Kira Kuschnerus; Nicolle Kraenkel; Chad E Brokopp; Frank Enseleit; Stephan Michels; Frank Ruschitzka; Thomas F Lüscher; Christian M Matter Journal: Int J Cardiol Date: 2013-04-02 Impact factor: 4.164
Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079
Authors: Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins Journal: Cochrane Database Syst Rev Date: 2019-03-04
Authors: Federico Ricci; Francesco Bandello; Pierluigi Navarra; Giovanni Staurenghi; Michael Stumpp; Marco Zarbin Journal: Int J Mol Sci Date: 2020-11-03 Impact factor: 5.923
Authors: Daniel A Benisek; Julio Manzitti; Daniel Scorsetti; Andres M Rousselot Ascarza; Amalia A Ascarza; Diego Gomez Rancaño; Romina Quercia; Matias Ramirez Gismondi; Mateo A Carpio Total; María L Scorsetti; Eduardo Spitzer; Carola Lombas; Matías Deprati; María Ines Penna; Francisco Fernández; Marcelo A Tinelli Journal: Exp Ther Med Date: 2020-10-09 Impact factor: 2.447